Given that a recombinant human IL-1RA is approved for use in human peripheral inflammatory conditions (anakinra), we thought it feasible that increasing IL-1RA, and thus reducing IL-1 signaling through IL-1R, might be a rational approach to moderating inflammation in AD. This evidence concerns the gene IL1R1 and Alzheimer disease.